Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Cash from Financing Activities data on record, last reported at $274.5 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million; the TTM value through Sep 2025 reached $314.9 million, up 49.19%, while the annual FY2024 figure was $255.6 million, 91.37% up from the prior year.
  • Cash from Financing Activities reached $274.5 million in Q3 2025 per DNTH's latest filing, up from $568000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $274.5 million in Q3 2025 and bottomed at -$4.9 million in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $69.2 million, with a median of $568000.0 recorded in 2025.
  • The widest YoY moves for Cash from Financing Activities: up 92640.88% in 2025, down 99.93% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $96.6 million in 2022, then crashed by 105.03% to -$4.9 million in 2023, then soared by 915.54% to $39.7 million in 2024, then skyrocketed by 591.89% to $274.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $274.5 million in Q3 2025, $568000.0 in Q2 2025, and $161000.0 in Q1 2025.